MARKET INTELLIGENCE·Capacity Update
Sanofi Secures FDA Expansion for Type 1 Diabetes Drug Tzield, Boosting Market Access
Sanofi has secured an FDA expansion for its Type 1 diabetes treatment, Tzield, following a two-month delay under the Commissioner’s National Priority Voucher (CNPV) program. This regulatory milestone significantly broadens market access for Tzield, compelling procurement directors and supply chain VPs to reassess demand forecasts and manufacturing readiness to capitalize on this expanded commercial opportunity.
90-Day Activity